Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
This blend is provided as acetate salts for enhanced solubility in research protocols
Disclosure of interest: Khudayarova S.M.:nothing to disclose, Rakhmatullayeva G.K.: nothing to disclose E-Posters - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P2555 - ESOC25-2084 AN EVALUATION OF MEDICAL MANAGEMENT FOR SECONDARY PREVENTION OF ISCHAEMIC STROKE IN A TERTIARY STROKE CENTRE Nicole Cosgrave 1,2 , Basmah Karembaks 1 , Vanessa Farnan 1,2 , Anne-Marie Liddy 2 , Rory Durcan 2 , Karl Boyle 2 , David Williams 1,2 1 Department of Medicine, RCSI University of Medicine and Health Sciences, Dublin, Ireland, 2 Department of Geriatrics and Stroke Medicine, Beaumont Hospital, Dublin, Ireland Background and Aims: Recurrent ischaemic strokes occur in 9-15% of patients within one year
Retatrutide is a synthetic peptide based on a glucose-dependent insulinotropic polypeptide (GIP) backbone, but uniquely, it functions as a triple agonist
Do not skip doses
Angiogenesis & localised signalling
Noise and Health
US$ 26.14
US$ 28.84
US$ 22.95
US$ 26.78
US$ 21.20